ML-007 is under clinical development by MapLight therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ML-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ML-007 overview
ML-007 is under development for the treatment of Alzheimer’s disease psychosis and schizophrenia. The therapeutic candidate is a combination product targets muscarinic acetylcholine receptor M1 and muscarinic acetylcholine receptor M4. The drug candidate is being developed based on optogenetics and STARmap (three-dimensional spatial transcriptomics) platform. It is administered through oral route.
It was also under development for the treatment of dyskinesia.
MapLight therapeutics overview
MapLight therapeutics. (formerly Alvarado Therapeutics, Inc.), is a biopharmaceutical company focusing on drug discovery for diseases of the central nervous system. The company is headquartered in United States.
For a complete picture of ML-007’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
